Atea Pharmaceuticals presents new data on combo of bemnifosbuvir, ruzasvir

Atea Pharmaceuticals announced the Company will present new efficacy results, including SVR12 data, from the Phase 2 lead-in cohort evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus at the European Association for the Study of the Liver, EASL, Congress 2024, taking place June 5-8, 2024 in Milan, Italy. “Despite current HCV treatments, progress toward eliminating the virus in the U.S. has slowed, and new chronic cases exceed cure rates. In the decade since the first direct acting antiviral treatments were introduced, both the virus and the patient population have changed significantly, including the emergence of resistant mutations,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. “We need new HCV treatments that address the needs of today’s patients and feature a best-in-class treatment profile with high antiviral potency, short treatment duration, potential for low risk of drug-drug interactions and a high barrier to resistance. We look forward to sharing our data at EASL Congress 2024, which will reinforce the potential of this combination to treat HCV as it exists today.”